Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by With Shortchain Fatty Acids Enriched Drink

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06951386Not ApplicableRecruiting

The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabolic Syndrome

NCT05021341Not ApplicableCompletedPrimary

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

NCT00891124CompletedPrimary

Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).

Showing all 3 trials

Research Network

Common Treatments

  • With Shortchain Fatty Acids Enriched Drink1
  • Berberine1
  • Dihydroberberine 2001
  • Dihydroberberine 1001
  • Unenriched Oat Drink1

Active Sponsors

  • AstraZeneca1
  • KU Leuven1
  • NNB Nutrition1
  • Lindenwood University1

Top Investigators

Related Conditions

  • Anthropometry1
  • Body Composition1
  • Metabolomics1
  • Hyperlipidemia1
  • Energy Expenditure1

Activity Timeline